DS
CGON icon

David Shaw’s CG Oncology CGON Stock Holding History

David Shaw’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.35M Buy
89,417
+42,807
+92% +$2.8M ﹤0.01% 2206
2026
Q1 		$3.15M Buy
46,610
+23,582
+102% +$1.34M ﹤0.01% 2544
2025
Q4 		$956K Buy
23,028
+413
+2% +$17.1K ﹤0.01% 3572
2025
Q3 		$911K Buy
22,615
+12,115
+115% +$352K ﹤0.01% 3516
2025
Q2 		$273K Buy
+10,500
New +$253K ﹤0.01% 3924

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's CGON Position: Q2 2026 in Review

David Shaw increased its CG Oncology (CGON) stake by 92% in Q2 2026, buying an estimated $2.8M and bringing the position to 89,417 shares worth $6.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2206.

David Shaw first reported a position in CGON in Q2 2025 and has held it in 5 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • David Shaw held 89,417 shares of CG Oncology worth $6.35M as of Q2 2026.
  • David Shaw bought 42,807 CG Oncology shares in Q2 2026, an estimated $2.8M.
  • CG Oncology made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2206 holding.
  • David Shaw first reported a position in CG Oncology in Q2 2025 and has held it in 5 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.